RBX-7455 is under clinical development by MikrobEX and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect RBX-7455’s likelihood of approval (LoA) and phase transition for Clostridioides difficile Infections (Clostridium difficile Associated Disease) took place on 02 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their RBX-7455 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

RBX-7455 overview

RBX-7455 is under development for the prevention of Clostridium difficile infections, hepatic encephalopathy and Crohn's disease. The drug candidate is administered through oral route as a capsule. It constitutes fecal microbiota suspension which contains live microbes. The therapeutic candidate is developed based on microbial restoration therapy (MRT) platform.

MikrobEX overview

Rebiotix Inc (Rebiotix), a subsidiary of Ferring Holding SA, is a clinical stage biotechnology company that develops treatments for debilitating diseases. The company’s pipeline products include RBX2660, RBX7455. Its RBX2660 is available in the form of enema formulation used for the treatment recurrent clostridium difficile infection. Rebiotix’s RBX7455 is an oral formulation in a lyophilized form. The company partners with physicians to evaluate the use of Microbiota Restoration Therapy (MRT) for ulcerative colitis, crohn’s disease, chronic idiopathic constipation, myoclonus dystonia, autism, urea cycle disorders, chronic fatigue syndrome hepatic encephalopathy and multi drug-resistant organisms. Rebiotix is headquartered in Roseville, Minnesota, the US.

Quick View RBX-7455 LOA Data

Report Segments
  • Innovator
Drug Name
  • RBX-7455
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.